1. |
Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health 2019;85:8.
|
2. |
Zhang HW, Wang F, Zhou YQ, Xu SP, Yu SY, Zhang ZG. Morphine suppresses liver cancer cell tumor properties in vitro and in vivo. Front Oncol 2021;11:666446.
|
3. |
Kim JY, Ahn HJ, Kim JK, Kim J, Lee SH, Chae HB. Morphine suppresses lung cancer cell proliferation through the interaction with opioid growth factor receptor: An in vitro and human lung tissue study. Anesth Analg 2016;123:1429-36.
|
4. |
Wang K, Wang J, Wei F, Zhao N, Yang F, Ren X. Expression of TLR4 in non-small cell lung cancer is associated with PD-L1 and poor prognosis in patients receiving pulmonectomy. Front Immunol 2017;8:456.
|
5. |
Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol Life Sci 2021;78:1233-61.
|
6. |
Hu J, Xu J, Feng X, Li Y, Hua F, Xu G. Differential expression of the TLR4 gene in pan-cancer and its related mechanism. Front Cell Dev Biol 2021;9:700661.
|
7. |
Balducci C, Forloni G. The Role of Toll-Like Receptor 4 in Infectious and Non Infectious Inflammation. New York City: Springer; 2021.
|
8. |
Li J, Yang F, Wei F, Ren X. The role of toll-like receptor 4 in tumor microenvironment. Oncotarget 2017;8:66656-67.
|
9. |
Naderi J, Samani F, Amooheidari A, Javanmard SH, Vahabzadeh G, Vaseghi G. Evaluation of effects of morphine and ionizing radiation in cancer cell lines. J Cancer Res Ther 2019;15:S144-52.
|
10. |
Haghjooy-Javanmard S, Ghasemi A, Laher I, Zarrin B, Dana N, Vaseghi G. Influence of morphine on TLR4/NF-kB signaling pathway of MCF-7 cells. Bratisl Lek Listy 2018;119:229-33.
|
11. |
Ou T, Lilly M, Jiang W. The pathologic role of toll-like receptor 4 in prostate cancer. Front Immunol 2018;9:1188.
|
12. |
Gu J, Liu Y, Xie B, Ye P, Huang J, Lu Z. Roles of toll-like receptors: From inflammation to lung cancer progression. Biomed Rep 2018;8:126-32.
|
13. |
Nicholson AB, Watson GR, Derry S, Wiffen PJ. Methadone for cancer pain. Cochrane Database Syst Rev 2017;2:CD003971.
|
14. |
Maher DP, Walia D, Heller NM. Suppression of human natural killer cells by different classes of opioids. Anesth Analg 2019;128:1013-21.
|
15. |
Jantzie LL, Maxwell JR, Newville JC, Yellowhair TR, Kitase Y, Madurai N, et al. Prenatal opioid exposure: The next neonatal neuroinflammatory disease. Brain Behav Immun 2020;84:45-58.
|
16. |
Brawanski K, Brockhoff G, Hau P, Vollmann-Zwerenz A, Freyschlag C, Lohmeier A, et al. Efficacy of D, L-methadone in the treatment of glioblastoma in vitro. CNS Oncol 2018;7:CNS18.
|
17. |
Harper P, Hald O, Lwaleed BA, Kyyaly A, Johnston D, Cooper AJ, et al. The impact of morphine treatment on bladder cancer cell proliferation and apoptosis: In vitro studies. Exp Oncol 2018;40:190-3.
|
18. |
Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009;458:1191-5.
|
19. |
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785-91.
|
20. |
Hutchinson MR, Lewis SS, Coats BD, Rezvani N, Zhang Y, Wieseler JL, et al. Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience 2010;167:880-93.
|
21. |
Mostashari-Rad T, Arian R, Sadri H, Mehridehnavi A, Mokhtari M, Ghasemi F, et al. Study of CXCR4 chemokine receptor inhibitors using QSPR and molecular docking methodologies. J Theor Comput Chem 2019;18:1950018.
|
22. |
Wei F, Yang F, Li J, Zheng Y, Yu W, Yang L, et al. Soluble toll-like receptor 4 is a potential serum biomarker in non-small cell lung cancer. Oncotarget 2016;7:40106-14.
|
23. |
Jacobsen JH, Buisman-Pijlman FT, Mustafa S, Rice KC, Hutchinson MR. The efficacy of (+)-Naltrexone on alcohol preference and seeking behaviour is dependent on light-cycle. Brain Behav Immun 2018;67:181-93.
|
24. |
Zhang P, Yang M, Chen C, Liu L, Wei X, Zeng S. Toll-like receptor 4 (TLR4)/opioid receptor pathway crosstalk and impact on opioid analgesia, immune function, and gastrointestinal motility. Front Immunol 2020;11:1455.
|
25. |
Dana N, Vaseghi G, Haghjooy Javanmard S. Crosstalk between peroxisome proliferator-activated receptors and toll-like receptors: A systematic review. Adv Pharm Bull 2019;9:12-21.
|
26. |
Dana N, Vaseghi G. PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling. J Pharm Pharm Sci 2019;22:418-23.
|
27. |
Michalska M, Katzenwadel A, Wolf P. Methadone as a “tumor theralgesic” against cancer. Front Pharmacol 2017;8:733.
|
28. |
Theile D, Mikus G. Methadone against cancer: Lost in translation. Int J Cancer 2018;143:1840-8.
|